Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$19.67 USD

19.67
4,324,041

+0.84 (4.46%)

Updated Nov 6, 2024 04:00 PM ET

Pre-Market: $19.77 +0.10 (0.51%) 9:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

by Zacks Equity Research

Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

by Zacks Equity Research

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

by Zacks Equity Research

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

UnitedHealth Group (UNH) Q4 Earnings Beat on Membership Growth

by Zacks Equity Research

UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.

Best Momentum Stocks to Buy for January 11th (Revised)

by Zacks Equity Research

ADMA and ARQT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Best Momentum Stocks to Buy for January 11th

by Zacks Equity Research

ADMA, ARQT and PHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.

Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

by Zacks Equity Research

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.

New Strong Buy Stocks for January 11th

by Zacks Equity Research

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

by Zacks Equity Research

Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal

by Zacks Equity Research

Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.

Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues

by Zacks Equity Research

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues

by Zacks Equity Research

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint

by Zacks Equity Research

Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.

Are You Looking for a Top Momentum Pick? Why Adma Biologics (ADMA) is a Great Choice

by Zacks Equity Research

Does Adma Biologics (ADMA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

by Zacks Equity Research

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

Ultragenyx (RARE) Posts Update From AS Study of GTX-102

by Zacks Equity Research

Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

by Zacks Equity Research

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

by Zacks Equity Research

Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

by Zacks Equity Research

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

by Zacks Equity Research

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

by Zacks Equity Research

Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.